Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vobramitamab duocarmazine + lorigerlimab in advanced solid tumors
NCT05293496Phase 1Completed
- Sponsor
- MacroGenics
- Start
- Apr 2022
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of vobramitamab duocarmazine in metastatic castration-resistant prostate cancer (mCRPC), melanoma, pancreatic cancer (PC) and 3 more (7 cohorts), sponsored by MacroGenics. Primary endpoints: Adverse Events at 2 years, Serious Adverse Events at 2 years and 1 more. Started Apr 2022; status: completed.
02
Drugs
vobramitamab duocarmazine
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)melanomapancreatic cancer (PC)hepatocellular carcinoma (HCC)ovarian cancer
Beyond the preview
Go deeper on NCT05293496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05293496.